Product logins

Find logins to all Clarivate products below.


Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2024

Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective, safer, and better-tolerated therapies, such as sodium-glucose cotransporter 2 (SGLT- 2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonists, has provided physicians with a broad array of therapeutic options. Moreover, with a better understanding of T2D and its complications, treatment of the disease is becoming more individualized. Numerous branded agents from both established and recently launched classes are now jostling for position in the treatment paradigm.

Questions answered

  • What patient shares do key therapies garner by line of therapy in newly diagnosed T2D patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed T2D patients?
  • How have Brenzavvy and Mounjaro been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of T2D patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of T2D patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Humalog, Jardiance, Lantus, metformin, Mounjaro, Novolog, Ozempic, Rybelsus, Toujeo, Trulicity

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…